{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Showing 1 - 6 of 6 results
Status:
US Approved Allergenic Extract
(1994)
Source:
BLA103738
(1994)
Source URL:
First approved in 1994
Source:
BLA103738
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Geraniol is a dietary monoterpene alcohol that
is found in the essential oils of aromatic plants. To date,
experimental evidence supports the therapeutic or preventive
effects of geraniol on different types of cancer, such as breast,
lung, colon, prostate, pancreatic, and hepatic cancer, and has
revealed the mechanistic basis for its pharmacological actions.
In addition, geraniol sensitizes tumor cells to commonly used
chemotherapy agents. Geraniol controls a variety of signaling
molecules and pathways that represent tumor hallmarks;
these actions of geraniol constrain the ability of tumor cells
to acquire adaptive resistance against anticancer drugs. It has been shown that geraniol inhibits
HMG-CoA reductase in most types of tumor cells, which
raises the possibility that the reduced prenylation of small
G-proteins, such as Ras or RhoA, accounts for the antitumor
effects of geraniol. In addition to its use in various commercial
products, including cosmetics and fine fragrances, geraniol
exerts a broad spectrum of pharmacological activities, such
as anti-microbial, anti-inflammatory, anti-oxidant, anti-ulcer
and neuroprotective activities. Geraniol is classified into the generally recognized-as-safe
(GRAS) category by the Flavor and
Extract Manufacturers Association (FEMA) and the Food
and Drug Administration (FDA) of the United States.
Status:
Possibly Marketed Outside US
Source:
NDA212728
(2020)
Source URL:
First approved in 2020
Source:
NDA212728
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
First approved in 2000
Source:
21 CFR 348
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Borneol, a monoterpenoid alcohol, is a component of many essential oils. Barneol occurs in nature as a single enantiomer (d- or l-, depending on the oil type) or, less frequently, as the racemate. Several studies have proved the effectiveness of borneol. In Chinese medicines borneol has been used in relieving symptoms of anxiety, fatigue and insomnia; inducing anesthesia and analgesia to alleviate abdominal pain, wounds and burns; relieving rheumatic pain, hemorrhoids, skin diseases and ulcerations of the mouth, ears, eyes or nose; to treat sore throats and skin infections, and is mainly used to treat cardiovascular and cerebrovascular diseases. Borneol has a significant therapeutic effect on neuralgia. This compound is considered a GRAS approved by the FDA as food flavor. Additionally, borneol is a fragrance ingredient. GABAA, TRPV3, TRPM8 and TRPA1 have been identified as the molecular targets of borneol.
Status:
US Approved Allergenic Extract
(1994)
Source:
BLA103738
(1994)
Source URL:
First approved in 1994
Source:
BLA103738
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Geraniol is a dietary monoterpene alcohol that
is found in the essential oils of aromatic plants. To date,
experimental evidence supports the therapeutic or preventive
effects of geraniol on different types of cancer, such as breast,
lung, colon, prostate, pancreatic, and hepatic cancer, and has
revealed the mechanistic basis for its pharmacological actions.
In addition, geraniol sensitizes tumor cells to commonly used
chemotherapy agents. Geraniol controls a variety of signaling
molecules and pathways that represent tumor hallmarks;
these actions of geraniol constrain the ability of tumor cells
to acquire adaptive resistance against anticancer drugs. It has been shown that geraniol inhibits
HMG-CoA reductase in most types of tumor cells, which
raises the possibility that the reduced prenylation of small
G-proteins, such as Ras or RhoA, accounts for the antitumor
effects of geraniol. In addition to its use in various commercial
products, including cosmetics and fine fragrances, geraniol
exerts a broad spectrum of pharmacological activities, such
as anti-microbial, anti-inflammatory, anti-oxidant, anti-ulcer
and neuroprotective activities. Geraniol is classified into the generally recognized-as-safe
(GRAS) category by the Flavor and
Extract Manufacturers Association (FEMA) and the Food
and Drug Administration (FDA) of the United States.
Status:
Possibly Marketed Outside US
First approved in 2000
Source:
21 CFR 348
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Borneol, a monoterpenoid alcohol, is a component of many essential oils. Barneol occurs in nature as a single enantiomer (d- or l-, depending on the oil type) or, less frequently, as the racemate. Several studies have proved the effectiveness of borneol. In Chinese medicines borneol has been used in relieving symptoms of anxiety, fatigue and insomnia; inducing anesthesia and analgesia to alleviate abdominal pain, wounds and burns; relieving rheumatic pain, hemorrhoids, skin diseases and ulcerations of the mouth, ears, eyes or nose; to treat sore throats and skin infections, and is mainly used to treat cardiovascular and cerebrovascular diseases. Borneol has a significant therapeutic effect on neuralgia. This compound is considered a GRAS approved by the FDA as food flavor. Additionally, borneol is a fragrance ingredient. GABAA, TRPV3, TRPM8 and TRPA1 have been identified as the molecular targets of borneol.
Status:
Possibly Marketed Outside US
First approved in 2000
Source:
21 CFR 348
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Borneol, a monoterpenoid alcohol, is a component of many essential oils. Barneol occurs in nature as a single enantiomer (d- or l-, depending on the oil type) or, less frequently, as the racemate. Several studies have proved the effectiveness of borneol. In Chinese medicines borneol has been used in relieving symptoms of anxiety, fatigue and insomnia; inducing anesthesia and analgesia to alleviate abdominal pain, wounds and burns; relieving rheumatic pain, hemorrhoids, skin diseases and ulcerations of the mouth, ears, eyes or nose; to treat sore throats and skin infections, and is mainly used to treat cardiovascular and cerebrovascular diseases. Borneol has a significant therapeutic effect on neuralgia. This compound is considered a GRAS approved by the FDA as food flavor. Additionally, borneol is a fragrance ingredient. GABAA, TRPV3, TRPM8 and TRPA1 have been identified as the molecular targets of borneol.